From: Classification of gallbladder cancer by assessment of CD8+ TIL and PD-L1 expression
Subgroup I | Subgroup II | Subgroup III | Subgroup IV | |
---|---|---|---|---|
CD8high PD-L1− |
CD8high PD-L1+ |
CD8low PD-L1− |
CD8low PD-L1+ | |
Clinical parameters n (%) | (n = 12) | (n = 21) | (n = 18) | (n = 15) |
Age median (range) | 65 (50–79) | 64 (29–75) | 66 (48–79) | 70 (45–81) |
Sex (Female) | 7 (58%) | 12 (57%) | 10 (56%) | 9 (60%) |
TNM stage (III + IV) | 7 (58%) | 11 (52%) | 14 (78%) | 11 (73%) |
Risk factors | ||||
Gallstone | 3 (25%) | 13 (62%) | 11 (61%) | 9 (60%) |
Diabetes | 4 (33%) | 6 (29%) | 7 (39%) | 3 (20%) |
Hypertension | 4 (33%) | 8 (38%) | 8 (44%) | 5 (33%) |
Cholecystitis | 7 (58%) | 12 (57%) | 14 (78%) | 10 (67%) |
Jaundice | 0 (0%) | 6 (29%) | 4 (22%) | 4 (27%) |
Completed resection | 8 (67%) | 16 (76%) | 11 (61%) | 11 (73%) |
CEA (> 5 μg/L) | 2 (17%) | 5 (24%) | 4 (22%) | 9 (60%) |
CA19–9 (> 34 U/mL) | 4 (33%) | 13 (62%) | 11 (61%) | 7 (58%) |
Liver dysfunction | ||||
ALT (> 40 U/L) | ||||
AST (> 35 U/L) | 1 (8%) | 5 (24%) | 5 (28%) | 4 (27%) |
TBil (> 22.2 μmol/L) | 3 (25%) | 5 (24%) | 6 (33%) | 5 (33%) |
DBil (> 6.8 μmol/L) | 3 (25%) | 7 (33%) | 5 (28%) | 5 (33%) |
GGT (> 45 U/L) | 1 (8%) | 7 (33%) | 5 (28%) | 5 (33%) |
ALP (> 135 U/L) | 3 (25%) | 7 (33%) | 5 (28%) | 5 (33%) |
2 (17%) | 9 (43%) | 5 (28%) | 4 (27%) | |
Pathological features | ||||
Differentiation (Poor) | 5 (42%) | 12 (57%) | 9 (50%) | 12 (80%) |
Tumor size, cm (median, range) | 2.4 (0.6–7.5) | 3.5 (0.5–7.0) | 3.0 (0.6–6.0) | 2.0 (0.8–7.0) |
Immunohistochemistry | ||||
CD133+ in TCs, n (%) | 5 (42%) | 9 (43%) | 6 (33%) | 7 (58%) |
PD-1+ in TILs, n (%) | 7 (58%) | 9 (43%) | 6 (33%) | 11 (73%) |
PD-L2+ in TCs, n (%) | 5 (42%) | 17 (81%) | 9 (50%) | 13 (87%) |
CD8+ TILs density | 60.5 | 79 | 28 | 27 |
(median, range) | (47–167) | (49–275) | (4–42) | (8–46) |
Adjuvant treatment | ||||
Chemotherapy, n (%) | 7 (58%) | 12 (57%) | 13 (72%) | 8 (53%) |
Radiotherapy, n (%) | 2 (17%) | 5 (24%) | 4 (22%) | 4 (27%) |
Others, n (%) | 3 (25%) | 8 (33%) | 6 (33%) | 4 (27%) |
No, n (%) | 2 (17%) | 4 (19%) | 2 (11%) | 2 (13%) |
Palliative treatment at stage IV | ||||
With therapy, n (%) | 8 (67%) | 16 (76%) | 15 (83%) | 12 (80%) |
Without therapy, n (%) | 4 (33%) | 5 (24%) | 3 (17%) | 3 (20%) |